Continue to Expect a Limited Role for PCSK9 Inhibitors

You'll hear buzz about using the PCSK9 inhibitors, Repatha (evolocumab) or Praluent (alirocumab), in patients with CV disease....

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote